Dare Bioscience
DARE
15 hedge funds and large institutions have $37M invested in Dare Bioscience in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
17% less funds holding
Funds holding: 18 → 15 (-3)
29% less capital invested
Capital invested by funds: $52M → $37M (-$15M)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$113K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$83.7K |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
+$16.5K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$7.99K |
| 5 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$1.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$908K |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$263K |
| 3 |
Millennium Management
New York
|
-$93K |
| 4 |
Goldman Sachs
New York
|
-$16K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$10K |
DARE Hedge Fund Activity: Q3 2014 in Review
15 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q3 2014, worth a combined $37M — down 29% from $52M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of DARE and 3 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Vanguard Group, opening a new position worth an estimated $113K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $908K sold.
- 15 institutional investors held Dare Bioscience (DARE) as of Q3 2014, down from 18 in Q2 2014.
- Funds reported $37M of Dare Bioscience stock for Q3 2014, down 29% quarter-over-quarter.
- 3 funds opened new Dare Bioscience positions in Q3 2014 and 6 closed out, a net change of -3 holders.
- The largest Dare Bioscience buyer in Q3 2014 was Vanguard Group, an estimated $113K added.
- The largest Dare Bioscience seller in Q3 2014 was JP Morgan Chase, an estimated $908K sold.
Based on aggregated 13F filings for Q3 2014.